Effect of drug metabolizing enzyme gene polymorphism on selective estrogen receptor modulator pharmacokinetics in breast cancer (JBCRG-12)
Not Applicable
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000001665
- Lead Sponsor
- JBCRG(Japan Breast Cancer Research Group)
- Brief Summary
The CYP2D6 genotype was the major determinant for TAM activity (p < 0.01). Smoking status (p = 0.07) and the CYP2C19 phenotype (p = 0.07), but not the CYP2D6 genotype (p = 0.61), showed marginally significant effects on TOR activity.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 273
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CYP2D6 gene polymorphism Pharmacokinetics of tamoxifen and its active metabolites or toremifen and its active metabolites
- Secondary Outcome Measures
Name Time Method Adverse event Drug efficacy